En este video, la Dra. Velázquez Mañana analiza las mutaciones del EGFR, los diferentes subtipos de cáncer de pulmón y cómo determinar cuál es el mejor tratamiento en general. To watch the complete playlist, click here. Special thanks to Genentech, BMS, TakedaJohnson & Johnson, and Daiichi-Sankyo

In this Program, Drs. Arya Mariam Roy, Assistant Professor at The Ohio State University, Erick Saldanha, Medical Oncologist & Postdoctoral Clinical Fellow at Princess Margaret Cancer Centre, Guilherme Sacchi de Camargo Correia, Hematology and Oncology fellow at Mayo Clinic in Jacksonville, Florida

The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended. ¡Los vídeos están disponibles BAJO DEMANDA! Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO

Como parte de la Videoteca de Cáncer de Pulmón en Español 2023, el Dr. Alejandro R. Calvo, MD, FACP, aborda temas relacionados con el cáncer de pulmón, desde el diagnóstico hasta las opciones de tratamiento, y preguntas y conceptos erróneos comunes. Para ver la serie completa de click aquí.

The 2025 Targeted Therapies in Lung Cancer Patient Forum was a live, virtual, interactive patient education event presented in March 2025 and led by Dr. Lyudmila Bazhenova. It included presentations and panel discussions from 11 top medical professionals covering educational topics related to

Como parte de la Videoteca de Cáncer de Pulmón en Español 2025, oncólogos expertos discuten las opciones de tratamiento y la información más emergente en cáncer de pulmón. El Dr. Raez aborda la terapia para cánceres de pulmón EGFR y ALK, además de analizar otros tres temas de actualidad. La Dra

GRACE is excited to bring you a new series on current updates in Melanoma Treatment Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chiefof Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma service at Memorial Sloan Kettering and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

GRACE is excited to bring you a new series on current updates in Melanoma Treatment. Meredith McKean MD, MPH with Tennessee Oncology, Michael Postow, MD Chief of Melanoma Service at Memorial Sloan Kettering, and Sanjiv Agarwala, MD, Professor of Medical Oncology and Hematology at Temple University

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss combinations for first-line treatment - immunotherapy combined.

In this Spanish language audio recording, Dr. Luis Raez, MD FACP FCCP joined GRACE to discuss PDL1 as a biomarker for first-line treatment.